{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:11:10Z","timestamp":1791465070321,"version":"4.3.4"},"reference-count":172,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":1328,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA034634"],"award-info":[{"award-number":["R01DA034634"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s13311-019-00814-4","type":"journal-article","created":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T14:02:55Z","timestamp":1578319375000},"page":"55-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"title":["Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7455-7464","authenticated-orcid":false,"given":"Amanda J.","family":"Abraham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina M.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha J.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D.","family":"Friedmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-019-00814-4_bib1","series-title":"Key substance use and mental health indicators in the United States: results from the 2016 National Survey on Drug Use and Health","author":"Substance Abuse and Mental Health Services Administration","year":"2017"},{"issue":"10","key":"10.1007\/s13311-019-00814-4_bib2","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/MLR.0000000000000625","article-title":"The economic burden of prescription opioid overdose, abuse, and dependence in the united states, 2013","volume":"54","author":"Florence","year":"2016","journal-title":"Med Care"},{"key":"10.1007\/s13311-019-00814-4_bib3","unstructured":"Ahmad F, Rossen L, Spencer M, Warner M, Sutton P. Provisional drug overdose death counts; 2018. Available from: https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm. Accessed 1 June 2019"},{"issue":"5","key":"10.1007\/s13311-019-00814-4_bib4","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.amepre.2015.05.031","article-title":"2010 National and State Costs of Excessive Alcohol Consumption","volume":"49","author":"Sacks","year":"2015","journal-title":"Am J Prev Med"},{"key":"10.1007\/s13311-019-00814-4_bib5","doi-asserted-by":"crossref","first-page":"E109","DOI":"10.5888\/pcd11.130293","article-title":"Contribution of excessive alcohol consumption to deaths and years of potential life lost in the United States","volume":"11","author":"Stahre","year":"2014","journal-title":"Prev Chronic Dis"},{"key":"10.1007\/s13311-019-00814-4_bib6","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1007\/s13311-019-00814-4_bib7","doi-asserted-by":"crossref","unstructured":"Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev. 2011(10):Cd004147.","DOI":"10.1002\/14651858.CD004147.pub4"},{"key":"10.1007\/s13311-019-00814-4_bib8","doi-asserted-by":"crossref","unstructured":"Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev. 2011(9):Cd005031.","DOI":"10.1002\/14651858.CD005031.pub4"},{"issue":"Suppl 1","key":"10.1007\/s13311-019-00814-4_bib9","first-page":"S42","article-title":"Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience","volume":"13","author":"Amass","year":"2004","journal-title":"Am J Addict"},{"issue":"9792","key":"10.1007\/s13311-019-00814-4_bib10","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(11)61331-7","article-title":"Injectable extended-release naltrexone for opioid dependence","volume":"378","author":"Krupitsky","year":"2011","journal-title":"Lancet."},{"issue":"4","key":"10.1007\/s13311-019-00814-4_bib11","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1360-0443.2006.01369.x","article-title":"Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review","volume":"101","author":"Johansson","year":"2006","journal-title":"Addiction."},{"issue":"2","key":"10.1007\/s13311-019-00814-4_bib12","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/archpsyc.63.2.210","article-title":"Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial","volume":"63","author":"Comer","year":"2006","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"10.1007\/s13311-019-00814-4_bib13","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJMoa055255","article-title":"Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence","volume":"355","author":"Fiellin","year":"2006","journal-title":"N Engl J Med"},{"issue":"1\u20133","key":"10.1007\/s13311-019-00814-4_bib14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.drugalcdep.2008.06.016","article-title":"Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence","volume":"99","author":"Ziedonis","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"10.1007\/s13311-019-00814-4_bib15","unstructured":"National Academies of Sciences E, and Medicine. Medications for opioid use disorder save lives. Washington, DC; 2019."},{"key":"10.1007\/s13311-019-00814-4_bib16","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1360-0443.2004.00763.x","article-title":"Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review","volume":"99","author":"Bouza","year":"2004","journal-title":"Addiction."},{"key":"10.1007\/s13311-019-00814-4_bib17","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/archpsyc.1992.01820110045007","article-title":"Naltrexone and coping skills therapy for alcohol dependence: a controlled study","volume":"49","author":"O'Malley","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"10.1007\/s13311-019-00814-4_bib18","doi-asserted-by":"crossref","unstructured":"Rosner S, Hackl-Herrwerth A, Lehert LS, Vecchi S, Soyka M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2011(9).","DOI":"10.1002\/14651858.CD001867.pub3"},{"key":"10.1007\/s13311-019-00814-4_bib19","doi-asserted-by":"crossref","unstructured":"Rosner S, Hackl-Herrwerth A, Lehert LS, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2010(12).","DOI":"10.1002\/14651858.CD001867.pub3"},{"key":"10.1007\/s13311-019-00814-4_bib20","doi-asserted-by":"crossref","unstructured":"Srisurapanont M, Jarusuraisin N. Opioid antagonists for alcohol dependence. Cochrane Database Systematic Reviews. 2005.","DOI":"10.1002\/14651858.CD001867.pub2"},{"key":"10.1007\/s13311-019-00814-4_bib21","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1001\/archpsyc.1992.01820110040006","article-title":"Naltrexone in the treatment of alcohol dependence","volume":"49","author":"Volpicelli","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"10.1007\/s13311-019-00814-4_bib22","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1176\/ajp.152.4.613","article-title":"Effect of naltrexone on alcohol \u201chigh\u201d in alcoholics","volume":"152","author":"Volpicelli","year":"1995","journal-title":"Am J Psychiatr"},{"issue":"2","key":"10.1007\/s13311-019-00814-4_bib23","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1360-0443.2012.04054.x","article-title":"Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?","volume":"108","author":"Maisel","year":"2013","journal-title":"Addiction."},{"key":"10.1007\/s13311-019-00814-4_bib24","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.293.13.1617","article-title":"Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial","volume":"293","author":"Garbutt","year":"2005","journal-title":"J Am Med Assoc"},{"key":"10.1007\/s13311-019-00814-4_bib25","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/jcp.0b013e31814ce50d","article-title":"Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent prior to treatment","volume":"27","author":"O'Malley","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"10.1007\/s13311-019-00814-4_bib26","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/01.ALC.0000130804.08397.29","article-title":"Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo controlled clinical trial","volume":"28","author":"Kranzler","year":"2004","journal-title":"Alcohol Clin Exp Res"},{"issue":"5 Suppl","key":"10.1007\/s13311-019-00814-4_bib27","first-page":"77A","article-title":"Effect of long-acting injectable naltrexone on durability of drinking outcomes [Abstract]","volume":"29","author":"Gastfriend","year":"2005","journal-title":"Alcohol Clin Exp Res"},{"issue":"Supplement 1","key":"10.1007\/s13311-019-00814-4_bib28","first-page":"S69","article-title":"Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspective","volume":"12","author":"Soyka","year":"2003","journal-title":"Am J Addict"},{"issue":"2","key":"10.1007\/s13311-019-00814-4_bib29","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jsat.2006.06.002","article-title":"Naltrexone for probationers and parolees","volume":"31","author":"O'Brien","year":"2006","journal-title":"J Subst Abus Treat"},{"key":"10.1007\/s13311-019-00814-4_bib30","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.drugalcdep.2018.06.015","article-title":"Study characteristics influence the efficacy of substance abuse treatments: a meta-analysis of medications for alcohol use disorder","volume":"190","author":"Klemperer","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"10.1007\/s13311-019-00814-4_bib31","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1001\/jamapsychiatry.2014.3053","article-title":"Naltrexone vs placebo for the treatment of alcohol dependence: a randomized clinical trial","volume":"72","author":"Oslin","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1007\/s13311-019-00814-4_bib32","doi-asserted-by":"crossref","unstructured":"Brewer C, Meyers RJ, Johnsen J. Does disulfiram help to prevent relaspe in alcohol abuse? CNS Drugs 2000;14(5):329\u201341.","DOI":"10.2165\/00023210-200014050-00001"},{"key":"10.1007\/s13311-019-00814-4_bib33","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1192\/bjp.161.1.84","article-title":"Disulfiram treatment of alcoholism","volume":"161","author":"Chick","year":"1992","journal-title":"Br J Psychiatry"},{"issue":"1","key":"10.1007\/s13311-019-00814-4_bib34","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1360-0443.2004.00597.x","article-title":"Does disulfiram have a role in alcoholism treatment today?","volume":"99","author":"Fuller","year":"2004","journal-title":"Addiction."},{"issue":"3","key":"10.1007\/s13311-019-00814-4_bib35","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/01.jcp.0000222512.25649.08","article-title":"The status of disulfiram: a half of a century later","volume":"26","author":"Suh","year":"2006","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"10.1007\/s13311-019-00814-4_bib36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/ADM.0b013e3181d41ddb","article-title":"Adoption and implementation of medications in addiction treatment programs","volume":"5","author":"Knudsen","year":"2011","journal-title":"J Addict Med"},{"key":"10.1007\/s13311-019-00814-4_bib37","series-title":"Treatment Episode Data Set (TEDS): 2005-2015, National admissions to substance abuse treatment services","author":"Substance Abuse and Mental Health Services Administration","year":"2017"},{"issue":"22","key":"10.1007\/s13311-019-00814-4_bib38","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1001\/jama.2017.4760","article-title":"More treatments on deck for alcohol use disorder","volume":"317","author":"Lyon","year":"2017","journal-title":"JAMA."},{"issue":"2","key":"10.1007\/s13311-019-00814-4_bib39","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1080\/08897077.2015.1133472","article-title":"Potential medications for the treatment of alcohol use disorder: an evaluation of clinical efficacy and safety","volume":"37","author":"Litten","year":"2016","journal-title":"Subst Abus"},{"issue":"1","key":"10.1007\/s13311-019-00814-4_bib40","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pharmthera.2005.06.010","article-title":"Medications development: successes and challenges","volume":"108","author":"Vocci","year":"2005","journal-title":"Pharmacol Ther"},{"issue":"7","key":"10.1007\/s13311-019-00814-4_bib41","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1111\/acer.13093","article-title":"Discovery, development, and adoption of medications to treat alcohol use disorder: goals for the phases of medications development","volume":"40","author":"Litten","year":"2016","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1007\/s13311-019-00814-4_bib42","series-title":"Diffusion of Innovations","author":"Rogers","year":"2003"},{"issue":"8","key":"10.1007\/s13311-019-00814-4_bib43","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.2018.11406","article-title":"Diagnosis and Pharmacotherapy of alcohol use disorder: a review","volume":"320","author":"Kranzler","year":"2018","journal-title":"JAMA."},{"issue":"3","key":"10.1007\/s13311-019-00814-4_bib44","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1517\/17425251003641975","article-title":"Acamprosate","volume":"6","author":"Kennedy","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1007\/s13311-019-00814-4_bib45","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/01.ALC.0000108656.81563.05","article-title":"The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis","volume":"28","author":"Mann","year":"2004","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1007\/s13311-019-00814-4_bib46","first-page":"1335","article-title":"Efficacy of naltrexone and acamprosate in alcoholism treatment: a meta-analysis","volume":"25","author":"Kranzler","year":"2001","journal-title":"Alcohol Clin Exp Res"},{"issue":"4","key":"10.1007\/s13311-019-00814-4_bib47","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1530-0277.2002.tb02578.x","article-title":"Potential neuroprotective effects of acamprosate","volume":"26","author":"Koob","year":"2002","journal-title":"Alcohol Clin Exp Res"},{"issue":"4","key":"10.1007\/s13311-019-00814-4_bib48","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0893-133X(02)00368-8","article-title":"A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone","volume":"27","author":"Mason","year":"2002","journal-title":"Neuropsychopharmacology."},{"issue":"8","key":"10.1007\/s13311-019-00814-4_bib49","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/j.1530-0277.2010.01233.x","article-title":"Naltrexone selectively elevates GABAergic neuroactive steroid levels in heavy drinkers with the Asp40 allele of the OPRM1 gene: a pilot investigation","volume":"34","author":"Ray","year":"2010","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1007\/s13311-019-00814-4_bib50","doi-asserted-by":"crossref","unstructured":"Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev. 2011(2):CD001333.","DOI":"10.1002\/14651858.CD001333.pub4"},{"key":"10.1007\/s13311-019-00814-4_bib51","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/nyas.12538","article-title":"A pharmaceutical industry perspective on the economics of treatments for alcohol and opioid use disorders","volume":"1327","author":"Gastfriend","year":"2014","journal-title":"Ann N Y Acad Sci"},{"issue":"22","key":"10.1007\/s13311-019-00814-4_bib52","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMp1402780","article-title":"Medication-assisted therapies\u2014tackling the opioid-overdose epidemic","volume":"370","author":"Volkow","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-019-00814-4_bib53","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cct.2019.04.006","article-title":"Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON)","volume":"81","author":"Malone","year":"2019","journal-title":"Contemp Clin Trials"},{"key":"10.1007\/s13311-019-00814-4_bib54","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jsat.2015.10.003","article-title":"Extended-release naltrexone: a qualitative analysis of barriers to routine use","volume":"62","author":"Alanis-Hirsch","year":"2016","journal-title":"J Subst Abus Treat"},{"issue":"2","key":"10.1007\/s13311-019-00814-4_bib55","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1176\/appi.ajp.2018.17070732","article-title":"A randomized trial comparing extended-release injectable suspension and oral naltrexone, both combined with behavioral therapy, for the treatment of opioid use disorder","volume":"176","author":"Sullivan","year":"2019","journal-title":"Am J Psychiatry"},{"key":"10.1007\/s13311-019-00814-4_bib56","unstructured":"Center for Substance Abuse Treatment. The Determinations Report: a Report on the Physician Waiver Program Established by the Drug Addiction Treatment Act of 2000 (\u201cDATA\u201d). Rockville: Substance Abuse and Mental Health Services Administration & U.S. Department of Health and Human Services; 2006."},{"key":"10.1007\/s13311-019-00814-4_bib57","doi-asserted-by":"crossref","unstructured":"Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev. 2011(4):CD001333.","DOI":"10.1002\/14651858.CD001333.pub4"},{"issue":"3","key":"10.1007\/s13311-019-00814-4_bib58","doi-asserted-by":"crossref","first-page":"190","DOI":"10.7326\/M18-1397","article-title":"Overdose prevention through medical treatment of opioid use disorders","volume":"169","author":"Volkow","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1007\/s13311-019-00814-4_bib59","unstructured":"American Society of Addiction Medicine. The ASAM national practice guideline for the use of medications in the treatment of addiction involving opioid use. 2015."},{"issue":"1","key":"10.1007\/s13311-019-00814-4_bib60","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jsat.2008.09.003","article-title":"Opioid treatment programs in the Clinical Trials Network: representativeness and buprenorphine adoption","volume":"37","author":"Ducharme","year":"2009","journal-title":"J Subst Abus Treat"},{"issue":"2\u20133","key":"10.1007\/s13311-019-00814-4_bib61","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.drugalcdep.2006.08.013","article-title":"The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters","volume":"87","author":"Knudsen","year":"2007","journal-title":"Drug Alcohol Depend"},{"key":"10.1007\/s13311-019-00814-4_bib62","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1747-597X-3-17","article-title":"State policy influence on the early diffusion of buprenorphine in community treatment programs","volume":"3","author":"Ducharme","year":"2008","journal-title":"Subst Abuse Treatment Prev Policy"},{"issue":"4","key":"10.1007\/s13311-019-00814-4_bib63","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jsat.2006.03.013","article-title":"Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors","volume":"30","author":"Knudsen","year":"2006","journal-title":"J Subst Abus Treat"},{"issue":"3","key":"10.1007\/s13311-019-00814-4_bib64","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1475-6773.2007.00812.x","article-title":"Role of state policies in the adoption of naltrexone for substance abuse treatment","volume":"43","author":"Heinrich","year":"2008","journal-title":"Health Serv Res"},{"issue":"1","key":"10.1007\/s13311-019-00814-4_bib65","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/1475-6773.12093","article-title":"Adoption and diffusion of evidence-based addiction medications in substance abuse treatment","volume":"49","author":"Heinrich","year":"2014","journal-title":"Health Serv Res"},{"issue":"3","key":"10.1007\/s13311-019-00814-4_bib66","doi-asserted-by":"crossref","first-page":"460","DOI":"10.15288\/jsad.2010.71.460","article-title":"Early adoption of injectable naltrexone for alcohol-use disorders: findings in the private-treatment sector","volume":"71","author":"Abraham","year":"2010","journal-title":"J Stud Alcohol Drugs"},{"key":"10.1007\/s13311-019-00814-4_bib67","doi-asserted-by":"crossref","first-page":"258","DOI":"10.15288\/jsad.2013.74.258","article-title":"Disparities in access to physicians and medications for the treatment of substance use disorders between publicly and privately funded treatment programs in the United States","volume":"74","author":"Abraham","year":"2013","journal-title":"J Stud Alcohol Drugs"},{"issue":"4","key":"10.1007\/s13311-019-00814-4_bib68","doi-asserted-by":"crossref","first-page":"669","DOI":"10.15288\/jsad.2011.72.669","article-title":"A longitudinal examination of alcohol pharmacotherapy adoption in substance use disorder treatment programs: patterns of sustainability and discontinuation","volume":"72","author":"Abraham","year":"2011","journal-title":"J Stud Alcohol Drugs"},{"issue":"3","key":"10.1007\/s13311-019-00814-4_bib69","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jsat.2010.01.003","article-title":"The adoption of alcohol pharmacotherapies in the Clinical Trials Network: the influence of research network participation","volume":"38","author":"Abraham","year":"2010","journal-title":"J Subst Abus Treat"},{"issue":"4","key":"10.1007\/s13311-019-00814-4_bib70","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0740-5472(02)00241-6","article-title":"Adoption and implementation of new technologies in substance abuse treatment","volume":"22","author":"Roman","year":"2002","journal-title":"J Subst Abus Treat"},{"issue":"3","key":"10.1007\/s13311-019-00814-4_bib71","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.drugalcdep.2005.12.005","article-title":"Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability","volume":"83","author":"Koch","year":"2006","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"10.1007\/s13311-019-00814-4_bib72","doi-asserted-by":"crossref","first-page":"852","DOI":"10.15288\/jsad.2007.68.852","article-title":"Organizational-level predictors of adoption across time: naltrexone in private substance-use disorders treatment centers","volume":"68","author":"Oser","year":"2007","journal-title":"J Stud Alcohol Drugs"},{"issue":"4","key":"10.1007\/s13311-019-00814-4_bib73","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jsat.2007.08.003","article-title":"A categorical typology of naltrexone-adopting private substance abuse treatment centers","volume":"34","author":"Oser","year":"2008","journal-title":"J Subst Abus Treat"},{"issue":"2","key":"10.1007\/s13311-019-00814-4_bib74","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/ADM.0b013e3181b41a32","article-title":"Facilitating factors and barriers to the use of medications in publicly funded addiction treatment organizations","volume":"4","author":"Knudsen","year":"2010","journal-title":"J Addict Med"},{"issue":"1","key":"10.1007\/s13311-019-00814-4_bib75","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1176\/appi.ps.201100034","article-title":"Perceptions of the state policy environment and adoption of medications in the treatment of substance use disorders","volume":"63","author":"Knudsen","year":"2012","journal-title":"Psychiatr Serv"},{"issue":"4","key":"10.1007\/s13311-019-00814-4_bib76","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.evalprogplan.2011.02.004","article-title":"Barriers to the implementation of medication-assisted treatment for substance use disorders: the importance of funding policies and medical infrastructure","volume":"34","author":"Knudsen","year":"2011","journal-title":"Eval Program Plan"},{"issue":"3","key":"10.1007\/s13311-019-00814-4_bib77","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jsat.2005.02.003","article-title":"Adoption of naltrexone to treat alcohol dependence","volume":"28","author":"Fuller","year":"2005","journal-title":"J Subst Abus Treat"},{"issue":"1","key":"10.1007\/s13311-019-00814-4_bib78","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11414-008-9132-4","article-title":"Substance abuse treatment organizations as mediators of social policy: slowing the adoption of a congressionally approved medication","volume":"37","author":"Wallack","year":"2008","journal-title":"J Behav Health Serv Res"},{"issue":"3","key":"10.1007\/s13311-019-00814-4_bib79","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s11414-009-9169-z","article-title":"Top manager effects on buprenorphine adoption in outpatient substance abuse treatment programs","volume":"37","author":"Friedmann","year":"2010","journal-title":"J Behav Health Serv Res"},{"issue":"2","key":"10.1007\/s13311-019-00814-4_bib80","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jsat.2005.05.002","article-title":"Buprenorphine diffusion: the attitudes of substance abuse treatment counselors","volume":"29","author":"Knudsen","year":"2005","journal-title":"J Subst Abus Treat"},{"issue":"1","key":"10.1007\/s13311-019-00814-4_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0740-5472(02)00319-7","article-title":"Research to practice: adoption of naltrexone in alcoholism treatment","volume":"24","author":"Thomas","year":"2003","journal-title":"J Subst Abus Treat"},{"issue":"3","key":"10.1007\/s13311-019-00814-4_bib82","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1177\/002204260503500308","article-title":"Organizational predictors of pharmocological innovation adoption: the case of disulfiram","volume":"35","author":"Knudsen","year":"2005","journal-title":"J Drug Issues"},{"issue":"Suppl 1","key":"10.1007\/s13311-019-00814-4_bib83","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/01.jcp.0000246209.18777.14","article-title":"Trends in the adoption of medications for alcohol dependence","volume":"26","author":"Ducharme","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"10.1007\/s13311-019-00814-4_bib84","series-title":"National Survey of Substance Abuse Treatment Services (N-SSATS)","author":"Substance Abuse and Mental Health Services Administration","year":"2017"},{"issue":"3","key":"10.1007\/s13311-019-00814-4_bib85","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jsat.2008.12.004","article-title":"Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network","volume":"37","author":"Knudsen","year":"2009","journal-title":"J Subst Abus Treat"},{"issue":"1","key":"10.1007\/s13311-019-00814-4_bib86","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/1077558713503188","article-title":"Adoption of evidence-based clinical innovations: the case of buprenorphine use by opioid treatment programs","volume":"71","author":"Andrews","year":"2014","journal-title":"Med Care Res Rev"},{"issue":"1","key":"10.1007\/s13311-019-00814-4_bib87","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1377\/hlthaff.2018.05162","article-title":"Medication treatment for opioid use disorders in substance use treatment facilities","volume":"38","author":"Mojtabai","year":"2019","journal-title":"Health Aff (Millwood)"},{"issue":"4","key":"10.1007\/s13311-019-00814-4_bib88","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1176\/appi.ps.201700196","article-title":"State-targeted funding and technical assistance to increase access to medication treatment for opioid use disorder","volume":"69","author":"Abraham","year":"2018","journal-title":"Psychiatr Serv"},{"issue":"3","key":"10.1007\/s13311-019-00814-4_bib89","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2105\/AJPH.2018.304856","article-title":"Impact of Medicaid restrictions on availability of buprenorphine in addiction treatment programs","volume":"109","author":"Andrews","year":"2019","journal-title":"Am J Public Health"},{"key":"10.1007\/s13311-019-00814-4_bib90","doi-asserted-by":"crossref","unstructured":"Maclean JC, Saloner B. The effect of public insurance expansions on substance use disorder treatment: evidence from the Affordable Care Act. 2017.","DOI":"10.3386\/w23342"},{"key":"10.1007\/s13311-019-00814-4_bib91","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jhealeco.2018.06.004","article-title":"The role of health insurance on treatment for opioid use disorders: evidence from the Affordable Care Act Medicaid expansion","volume":"60","author":"Meinhofer","year":"2018","journal-title":"J Health Econ"},{"issue":"3","key":"10.1007\/s13311-019-00814-4_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2019.04.002","article-title":"Medicaid coverage in substance use disorder treatment after the Affordable Care Act","volume":"102","author":"Andrews","year":"2019","journal-title":"J Subst Abus Treat"},{"issue":"4","key":"10.1007\/s13311-019-00814-4_bib93","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jsat.2008.08.004","article-title":"Research on the diffusion of evidence-based treatments within substance abuse treatment: a systematic review","volume":"36","author":"Garner","year":"2009","journal-title":"J Subst Abus Treat"},{"issue":"1","key":"10.1007\/s13311-019-00814-4_bib94","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2105\/AJPH.2016.303558","article-title":"The Affordable Care Act transformation of substance use disorder treatment","volume":"107","author":"Abraham","year":"2017","journal-title":"Am J Public Health"},{"key":"10.1007\/s13311-019-00814-4_bib95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2015.04.009","article-title":"Medicaid coverage of medications to treat alcohol and opioid dependence","volume":"55","author":"Mark","year":"2015","journal-title":"J Subst Abus Treat"},{"issue":"6","key":"10.1007\/s13311-019-00814-4_bib96","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.addbeh.2011.01.032","article-title":"Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation","volume":"36","author":"Roman","year":"2011","journal-title":"Addict Behav"},{"issue":"5","key":"10.1007\/s13311-019-00814-4_bib97","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s11920-011-0222-2","article-title":"Barriers to use of pharmacotherapy for addiction disorders and how to overcome them","volume":"13","author":"Oliva","year":"2011","journal-title":"Curr Psychiatry Rep"},{"issue":"6","key":"10.1007\/s13311-019-00814-4_bib98","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11920-017-0783-9","article-title":"Update on barriers to pharmacotherapy for opioid use disorders","volume":"19","author":"Sharma","year":"2017","journal-title":"Curr Psychiatry Rep"},{"key":"10.1007\/s13311-019-00814-4_bib99","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jsat.2018.01.010","article-title":"Do benefits restrictions limit Medicaid acceptance in addiction treatment? Results from a national study","volume":"87","author":"Andrews","year":"2018","journal-title":"J Subst Abus Treat"},{"issue":"4","key":"10.1007\/s13311-019-00814-4_bib100","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/08897077.2018.1449166","article-title":"A population-based examination of trends and disparities in medication treatment for opioid use disorders among Medicaid enrollees","volume":"39","author":"Stein","year":"2018","journal-title":"Subst Abus"},{"issue":"1","key":"10.1007\/s13311-019-00814-4_bib101","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jrh.12260","article-title":"Medication-assisted opioid treatment prescribers in Federally Qualified Health Centers: capacity lags in rural areas","volume":"34","author":"Jones","year":"2018","journal-title":"J Rural Health"},{"issue":"4","key":"10.1007\/s13311-019-00814-4_bib102","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/08897077.2016.1189477","article-title":"Medication-assisted treatment for substance use disorders within a national community health center research network","volume":"37","author":"Rieckmann","year":"2016","journal-title":"Subst Abus"},{"issue":"3","key":"10.1007\/s13311-019-00814-4_bib103","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11414-017-9553-z","article-title":"Treating opioid dependence with buprenorphine in the safety net: critical learning from clinical data","volume":"44","author":"Rieckmann","year":"2017","journal-title":"J Behav Health Serv Res"},{"key":"10.1007\/s13311-019-00814-4_bib104","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jsat.2018.08.002","article-title":"Access to treatment for alcohol use disorders following Oregon's health care reforms and Medicaid expansion","volume":"94","author":"McCarty","year":"2018","journal-title":"J Subst Abus Treat"},{"issue":"1","key":"10.1007\/s13311-019-00814-4_bib105","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13722-019-0160-6","article-title":"Medicaid expansion and treatment for opioid use disorders in Oregon: an interrupted time-series analysis","volume":"14","author":"McCarty","year":"2019","journal-title":"Addict Sci Clin Pract"},{"issue":"6","key":"10.1007\/s13311-019-00814-4_bib106","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/ADM.0000000000000164","article-title":"Patterns and Quality of buprenorphine opioid agonist treatment in a large Medicaid program","volume":"9","author":"Gordon","year":"2015","journal-title":"J Addict Med"},{"key":"10.1007\/s13311-019-00814-4_bib107","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","article-title":"Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population","volume":"85","author":"Morgan","year":"2018","journal-title":"J Subst Abus Treat"},{"issue":"7","key":"10.1007\/s13311-019-00814-4_bib108","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1176\/appi.ps.201000553","article-title":"Pharmacotherapy of alcohol use disorders by the Veterans Health Administration: patterns of receipt and persistence","volume":"63","author":"Harris","year":"2012","journal-title":"Psychiatr Serv"},{"issue":"4","key":"10.1007\/s13311-019-00814-4_bib109","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1176\/ps.2010.61.4.392","article-title":"Pharmacotherapy of alcohol use disorders in the Veterans Health Administration","volume":"61","author":"Harris","year":"2010","journal-title":"Psychiatr Serv"},{"key":"10.1007\/s13311-019-00814-4_bib110","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.drugalcdep.2017.06.011","article-title":"Variation in receipt of pharmacotherapy for alcohol use disorders across racial\/ethnic groups: a national study in the U.S. Veterans Health Administration","volume":"178","author":"Williams","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"10.1007\/s13311-019-00814-4_bib111","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/08897077.2018.1452327","article-title":"Medications for opioid use disorder in the Department of Veterans Affairs (VA) health care system: historical perspective, lessons learned, and next steps","volume":"39","author":"Wyse","year":"2018","journal-title":"Subst Abus"},{"issue":"3","key":"10.1007\/s13311-019-00814-4_bib112","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1080\/08897077.2018.1509251","article-title":"Underutilization of the current clinical capacity to provide buprenorphine treatment for opioid use disorders within the Veterans Health Administration","volume":"39","author":"Valenstein-Mah","year":"2018","journal-title":"Subst Abus"},{"issue":"4","key":"10.1007\/s13311-019-00814-4_bib113","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1037\/a0030949","article-title":"Pharmacotherapy for alcohol dependence: perceived treatment barriers and action strategies among Veterans Health Administration service providers","volume":"10","author":"Harris","year":"2013","journal-title":"Psychol Serv"},{"issue":"3","key":"10.1007\/s13311-019-00814-4_bib114","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0376-8716(03)00134-0","article-title":"Understanding US addiction physicians' low rate of naltrexone prescription","volume":"71","author":"Mark","year":"2003","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"10.1007\/s13311-019-00814-4_bib115","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jsat.2008.06.006","article-title":"Factors affecting willingness to provide buprenorphine treatment","volume":"36","author":"Netherland","year":"2009","journal-title":"J Subst Abus Treat"},{"issue":"2","key":"10.1007\/s13311-019-00814-4_bib116","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1370\/afm.1595","article-title":"Barriers to primary care physicians prescribing buprenorphine","volume":"12","author":"Hutchinson","year":"2014","journal-title":"Ann Fam Med"},{"issue":"2","key":"10.1007\/s13311-019-00814-4_bib117","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jsat.2010.05.004","article-title":"Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: national surveys of physicians","volume":"39","author":"Arfken","year":"2010","journal-title":"J Subst Abus Treat"},{"issue":"1","key":"10.1007\/s13311-019-00814-4_bib118","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1370\/afm.1735","article-title":"Geographic and specialty distribution of US physicians trained to treat opioid use disorder","volume":"13","author":"Rosenblatt","year":"2015","journal-title":"Ann Fam Med"},{"issue":"1","key":"10.1007\/s13311-019-00814-4_bib119","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jsat.2014.07.010","article-title":"Supply of buprenorphine waivered physicians: the influence of state policies","volume":"48","author":"Stein","year":"2015","journal-title":"J Subst Abus Treat"},{"issue":"3","key":"10.1007\/s13311-019-00814-4_bib120","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/1468-0009.12137","article-title":"Where is buprenorphine dispensed to treat opioid use disorders? The role of private offices, opioid treatment programs, and substance abuse treatment facilities in urban and rural counties","volume":"93","author":"Stein","year":"2015","journal-title":"Milbank Q"},{"issue":"11","key":"10.1007\/s13311-019-00814-4_bib121","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1001\/jama.2016.10542","article-title":"Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment","volume":"316","author":"Stein","year":"2016","journal-title":"JAMA."},{"issue":"6","key":"10.1007\/s13311-019-00814-4_bib122","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1377\/hlthaff.2014.1205","article-title":"Growth in buprenorphine waivers for physicians increased potential access to opioid agonist treatment, 2002-11","volume":"34","author":"Dick","year":"2015","journal-title":"Health Aff (Millwood)"},{"issue":"4","key":"10.1007\/s13311-019-00814-4_bib123","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/MLR.0000000000000703","article-title":"Impact of Medicaid expansion on Medicaid-covered utilization of buprenorphine for opioid use disorder treatment","volume":"55","author":"Wen","year":"2017","journal-title":"Med Care"},{"issue":"8","key":"10.1007\/s13311-019-00814-4_bib124","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","article-title":"National and state treatment need and capacity for opioid agonist medication-assisted treatment","volume":"105","author":"Jones","year":"2015","journal-title":"Am J Public Health"},{"issue":"3","key":"10.1007\/s13311-019-00814-4_bib125","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/add.14436","article-title":"Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder","volume":"114","author":"Jones","year":"2019","journal-title":"Addiction."},{"key":"10.1007\/s13311-019-00814-4_bib126","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.drugalcdep.2017.10.002","article-title":"Prescribing patterns of buprenorphine waivered physicians","volume":"181","author":"Thomas","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1007\/s13311-019-00814-4_bib127","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/jrh.12307","article-title":"Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update","volume":"35","author":"Andrilla","year":"2019","journal-title":"J Rural Health"},{"issue":"2","key":"10.1007\/s13311-019-00814-4_bib128","first-page":"31","article-title":"Buprenorphine maintenance for opioid dependence in public sector healthcare: benefits and barriers","volume":"1","author":"Duncan","year":"2015","journal-title":"J Addict Med Ther Sci"},{"key":"10.1007\/s13311-019-00814-4_bib129","unstructured":"Medicine ACoAA. Fellowship training opportunities 2019 [Available from: https:\/\/www.acaam.org\/applications-accreditation-now-accepted\/."},{"issue":"4","key":"10.1007\/s13311-019-00814-4_bib130","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1521-0391.2003.tb00543.x","article-title":"Barriers to the use of medications to treat alcoholism","volume":"12","author":"Mark","year":"2003","journal-title":"Am J Addict"},{"issue":"2","key":"10.1007\/s13311-019-00814-4_bib131","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jsat.2011.12.003","article-title":"Physicians in the substance abuse treatment workforce: understanding their employment within publicly funded treatment organizations","volume":"43","author":"Knudsen","year":"2012","journal-title":"J Subst Abus Treat"},{"issue":"1","key":"10.1007\/s13311-019-00814-4_bib132","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13722-019-0151-7","article-title":"Implementing alcohol use disorder pharmacotherapy in primary care settings: a qualitative analysis of provider-identified barriers and impact on implementation outcomes","volume":"14","author":"Hagedorn","year":"2019","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"10.1007\/s13311-019-00814-4_bib133","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/00981389.2012.725457","article-title":"Social workers' knowledge and perceptions of effectiveness and acceptability of medication assisted treatment of substance use disorders","volume":"52","author":"Bride","year":"2013","journal-title":"Soc Work Health Care"},{"key":"10.1007\/s13311-019-00814-4_bib134","doi-asserted-by":"crossref","unstructured":"Fiscella K, Wakeman SE, Beletsky L. Buprenorphine deregulation and mainstreaming treatment for opioid use disorder: X the X waiver. JAMA Psychiatry 2018.","DOI":"10.1001\/jamapsychiatry.2018.3685"},{"issue":"8","key":"10.1007\/s13311-019-00814-4_bib135","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.sapharm.2017.12.009","article-title":"Promising roles for pharmacists in addressing the U.S. opioid crisis","volume":"15","author":"Compton","year":"2017","journal-title":"Res Soc Adm Pharm"},{"issue":"3","key":"10.1007\/s13311-019-00814-4_bib136","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/00981389.2018.1564109","article-title":"The role of social work in the opioid epidemic: office-based opioid treatment programs","volume":"58","author":"Lombardi","year":"2019","journal-title":"Soc Work Health Care"},{"issue":"2","key":"10.1007\/s13311-019-00814-4_bib137","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/hsw\/hlt002","article-title":"Social work and implementation of the Affordable Care Act","volume":"38","author":"Andrews","year":"2013","journal-title":"Health Soc Work"},{"key":"10.1007\/s13311-019-00814-4_bib138","unstructured":"Association of American Medical Colleges. Physician supply and demand through 2025: key findings. 2015."},{"issue":"3","key":"10.1007\/s13311-019-00814-4_bib139","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.drugalcdep.2011.10.004","article-title":"Receipt of opioid agonist treatment in the Veterans Health Administration: facility and patient factors","volume":"122","author":"Oliva","year":"2012","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"10.1007\/s13311-019-00814-4_bib140","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.addbeh.2011.01.030","article-title":"Counselor attitudes toward the use of naltrexone in substance abuse treatment: a multi-level modeling approach","volume":"36","author":"Abraham","year":"2011","journal-title":"Addict Behav"},{"issue":"4","key":"10.1007\/s13311-019-00814-4_bib141","doi-asserted-by":"crossref","first-page":"628","DOI":"10.15288\/jsad.2009.70.628","article-title":"Counselor attitudes toward pharmacotherapies for alcohol dependence","volume":"70","author":"Abraham","year":"2009","journal-title":"J Stud Alcohol Drugs"},{"issue":"4","key":"10.1007\/s13311-019-00814-4_bib142","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jsat.2011.05.005","article-title":"A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatment","volume":"41","author":"Rieckmann","year":"2011","journal-title":"J Subst Abus Treat"},{"key":"10.1007\/s13311-019-00814-4_bib143","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13011-015-0009-2","article-title":"Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio","volume":"10","author":"Molfenter","year":"2015","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"2","key":"10.1007\/s13311-019-00814-4_bib144","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/alcalc\/agl100","article-title":"Knowledge and attitudes about pharmacotherapy for alcoholism: a survey of counselors and administrators in community-based addiction treatment centres","volume":"42","author":"Thomas","year":"2007","journal-title":"Alcohol Alcohol"},{"key":"10.1007\/s13311-019-00814-4_bib145","unstructured":"Facing Addiction in America: the Surgeon General's Report on Alcohol, Drugs, and Health. Reports of the Surgeon General. Washington (DC) 2016."},{"issue":"2","key":"10.1007\/s13311-019-00814-4_bib146","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1001\/jamapsychiatry.2018.3126","article-title":"Prevention and treatment of opioid misuse and addiction: a review","volume":"76","author":"Volkow","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1007\/s13311-019-00814-4_bib147","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/1475-6773.12686","article-title":"Geographic disparities in availability of opioid use disorder treatment for Medicaid enrollees","volume":"53","author":"Abraham","year":"2018","journal-title":"Health Serv Res"},{"issue":"2","key":"10.1007\/s13311-019-00814-4_bib148","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/1475-6773.13113","article-title":"County-level access to opioid use disorder medications in medicare Part D (2010-2015)","volume":"54","author":"Abraham","year":"2019","journal-title":"Health Serv Res"},{"key":"10.1007\/s13311-019-00814-4_bib149","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.drugalcdep.2014.06.012","article-title":"Unemployment and substance outcomes in the United States 2002-2010","volume":"142","author":"Compton","year":"2014","journal-title":"Drug Alcohol Depend"},{"key":"10.1007\/s13311-019-00814-4_bib150","unstructured":"The Henry J. Kaiser Family Foundation. Many people with substance abuse problems may find few to treat them2015 May 1, 2015. Available from: http:\/\/khn.org\/news\/the-many-people-with-substance-abuse-problems-may-find-few-to-treat-them\/."},{"issue":"1","key":"10.1007\/s13311-019-00814-4_bib151","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12875-017-0673-6","article-title":"Assessing and improving organizational readiness to implement substance use disorder treatment in primary care: findings from the SUMMIT study","volume":"18","author":"Ober","year":"2017","journal-title":"BMC Fam Pract"},{"issue":"10","key":"10.1007\/s13311-019-00814-4_bib152","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1001\/jamainternmed.2017.3947","article-title":"Collaborative care for opioid and alcohol use disorders in primary care: the SUMMIT Randomized Clinical Trial","volume":"177","author":"Watkins","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1007\/s13311-019-00814-4_bib153","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13012-015-0256-7","article-title":"An organizational readiness intervention and randomized controlled trial to test strategies for implementing substance use disorder treatment into primary care: SUMMIT study protocol","volume":"10","author":"Ober","year":"2015","journal-title":"Implement Sci"},{"key":"10.1007\/s13311-019-00814-4_bib154","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jsat.2015.06.010","article-title":"Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers","volume":"60","author":"LaBelle","year":"2016","journal-title":"J Subst Abus Treat"},{"issue":"4","key":"10.1007\/s13311-019-00814-4_bib155","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/ADM.0000000000000310","article-title":"Vermont hub-and-spoke model of care for opioid Use disorder: development, implementation, and impact","volume":"11","author":"Brooklyn","year":"2017","journal-title":"J Addict Med"},{"key":"10.1007\/s13311-019-00814-4_bib156","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jsat.2018.11.003","article-title":"Assessment of medication for opioid use disorder as delivered within the Vermont hub and spoke system","volume":"97","author":"Rawson","year":"2019","journal-title":"J Subst Abus Treat"},{"key":"10.1007\/s13311-019-00814-4_bib157","doi-asserted-by":"crossref","unstructured":"Miele GM, Caton L, Freese TE, McGovern M, Darfler K, Antonini VP, et al. Implementation of the hub and spoke model for opioid use disorders in California: rationale, design and anticipated impact. J Subst Abus Treat 2019.","DOI":"10.1016\/j.jsat.2019.07.013"},{"key":"10.1007\/s13311-019-00814-4_bib158","doi-asserted-by":"crossref","unstructured":"Reif S, Brolin MF, Stewart MT, Fuchs TJ, Speaker E, Mazel SB. The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders. J Subst Abuse Treat. 2019.","DOI":"10.1016\/j.jsat.2019.07.007"},{"issue":"3","key":"10.1007\/s13311-019-00814-4_bib159","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/08897077.2018.1543382","article-title":"No end to the crisis without an end to the waiver","volume":"39","author":"Frank","year":"2018","journal-title":"Subst Abus"},{"issue":"1","key":"10.1007\/s13311-019-00814-4_bib160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMp1802741","article-title":"Primary care and the opioid-overdose crisis\u2014buprenorphine myths and realities","volume":"379","author":"Wakeman","year":"2018","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1007\/s13311-019-00814-4_bib161","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1001\/jama.2019.0834","article-title":"Nurse practitioner and physician assistant waivers to prescribe buprenorphine and state scope of practice restrictions","volume":"321","author":"Spetz","year":"2019","journal-title":"JAMA."},{"key":"10.1007\/s13311-019-00814-4_bib162","doi-asserted-by":"crossref","unstructured":"Andrilla CHA, Patterson DG, Moore TE, Coulthard C, Larson EH. Projected contributions of nurse practitioners and physicians assistants to buprenorphine treatment services for opioid use disorder in rural areas. Med Care Res Rev. 2018:1077558718793070.","DOI":"10.1177\/1077558718793070"},{"issue":"8","key":"10.1007\/s13311-019-00814-4_bib163","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1377\/hlthaff.2018.0272","article-title":"Medicaid benefits for addiction treatment expanded after implementation of the Affordable Care Act","volume":"37","author":"Andrews","year":"2018","journal-title":"Health Aff (Millwood)"},{"issue":"2","key":"10.1007\/s13311-019-00814-4_bib164","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/02791072.2017.1300360","article-title":"Commercial health plan coverage of selected treatments for opioid use disorders from 2003 to 2014","volume":"49","author":"Reif","year":"2017","journal-title":"J Psychoactive Drugs"},{"key":"10.1007\/s13311-019-00814-4_bib165","unstructured":"Here's what it would cost to fix the opioid crisis, according to 5 experts: money; 2017 [Available from: http:\/\/money.com\/money\/5032445\/cost-fix-opioid-crisis\/."},{"key":"10.1007\/s13311-019-00814-4_bib166","doi-asserted-by":"crossref","unstructured":"Leggio L, Falk DE, Ryan ML, Fertig J, Litten RZ. Medication development for alcohol use disorder: a focus on clinical studies. Handb Exp Pharmacol. 2019.","DOI":"10.1007\/164_2019_295"},{"issue":"3","key":"10.1007\/s13311-019-00814-4_bib167","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1369-1600.2012.00454.x","article-title":"Medications development to treat alcohol dependence: a vision for the next decade","volume":"17","author":"Litten","year":"2012","journal-title":"Addict Biol"},{"issue":"9","key":"10.1007\/s13311-019-00814-4_bib168","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1111\/acer.13829","article-title":"Overcoming the \u201cValley of Death\u201d in medications development for alcohol use disorder","volume":"42","author":"Ray","year":"2018","journal-title":"Alcohol Clin Exp Res"},{"issue":"9","key":"10.1007\/s13311-019-00814-4_bib169","doi-asserted-by":"crossref","first-page":"eaax4043","DOI":"10.1126\/sciadv.aax4043","article-title":"Advances in the science and treatment of alcohol use disorder","volume":"5","author":"Witkiewitz","year":"2019","journal-title":"Sci Adv"},{"issue":"6","key":"10.1007\/s13311-019-00814-4_bib170","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial","volume":"178","author":"Lofwall","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"4","key":"10.1007\/s13311-019-00814-4_bib171","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1056\/NEJMsr1706626","article-title":"The role of science in addressing the opioid crisis","volume":"377","author":"Volkow","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1007\/s13311-019-00814-4_bib172","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41386-018-0292-5","article-title":"NIDA's medication development priorities in response to the opioid crisis: ten most wanted","volume":"44","author":"Rasmussen","year":"2019","journal-title":"Neuropsychopharmacology."}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-019-00814-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-019-00814-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923013776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923013776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-019-00814-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:58:12Z","timestamp":1761807492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923013776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":172,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1878747923013776"],"URL":"https:\/\/doi.org\/10.1007\/s13311-019-00814-4","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-019-00814-4","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}